Role of aberrant crypt foci detected using high-magnification-chromoscopic colonoscopy in human colorectal carcinogenesis

Journal of Gastroenterology and Hepatology (Australia)

Volumn 20, Issue 2, 2005, Pages 173-181

  Hurlstone, David P ^a   Cross, Simon S ^b  

^a ROYAL HALLAMSHIRE HOSPITAL   (United Kingdom)

^b UNIVERSITY OF SHEFFIELD   (United Kingdom)

Author keywords

Aberrant crypt foci; Chromoscopy; Early colorectal cancer; Magnification colonoscopy

Indexed keywords

BIOLOGICAL MARKER; INDIGO CARMINE;

APOPTOSIS; CELL PROLIFERATION; CHROMOENDOSCOPY; COLON ADENOMA; COLON CARCINOGENESIS; COLONOSCOPY; COLORECTAL CANCER; CRYPT CELL; DISEASE CLASSIFICATION; DYSPLASIA; EARLY CANCER; FAMILIAL COLON POLYPOSIS; HIGH MAGNIFICATION CHROMOSCOPIC COLONOSCOPY; HISTOPATHOLOGY; HUMAN; MALIGNANT TRANSFORMATION; PRECANCER; PRIORITY JOURNAL; REVIEW;

EID: 14844299317     PISSN: 08159319     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1440-1746.2004.03433.x     Document Type: Review

References (80)

1. Morson BC. Precancerous and early malignant lesions of the large intestine. Br. J. Surg. 1968; 55: 725-31.
2. Morson BC. Evolution of cancer of the colon and rectum. Proc. Inst. Med. Chic. 1974; 30: 145-8.
3. Bedenne L, Faivre J, Boutron MC et al. Adenoma carcinoma sequence or 'de novo' carcinogenesis? A study of adenomatous remnants in a population-based series of large bowel cancers. Cancer 1992; 69: 883-8.
4. Kuramoto S, Oohara T. Minute cancers arising de novo in the human large intestine. Cancer 1988; 61: 829-34.
5. Deschner EE. Experimentally induced cancer of the colon. Cancer 1974; 34: 824-8.
6. Davies MJ, Rumsby PC. Long-term analysis of colonic aberrant crypt formation after the treatment of Sprague-Dawley rats with azoxymethane. Teratog. Carcinog. Mutagen 1998; 18: 183-97.
7. Bird RP. Observation and quantification of aberrant crypts in the murine colon treated with a colon carcinogen: preliminary findings. Cancer Lett. 1987; 37: 147-51.
8. McLellan EA, Bird RP. Aberrant crypts: potential preneoplastic lesions in the murine colon. Cancer Res. 1988; 48: 6187-92.
9. Roncucci L, Pedroni F, Vaccina P et al. Aberrant crypt foci in colorectal carcinogenesis. Cell and crypt dynamics. Cell Prolif. 2000; 33: 1-18.
10. Adler DG, Gostout CJ, Sorbi D et al. Endoscopic identification and quantification of aberrant crypt foci in the human colon. Gastrointest. Endosc. 2002; 56: 657-62.
11. Takayama T, Katsuki S, Takahashi Y et al. Aberrant crypt foci of the colon as precursors of adenoma and cancer. N. Engl. J. Med. 1998; 339: 1277-84.
12. Tudec G, Bird RP, Bruce WR. Foci of aberrant crypts in the colons of mice and rats exposed to carcinogens associated with foods. Cancer Res. 1989; 49: 1236.
13. Nucci MR, Robinson CR, Longo P et al. Phenotypic and genotypic characteristics of aberrant crypt foci in human colorectal mucosa. Hum. Pathol. 1997; 28: 1396-407.
14. Roncucci L, Stamp D, Medline A et al. Identification and quantification of aberrant crypt foci and microadenomas in the human colon. Hum. Pathol. 1991; 22: 287.
15. Pretlow TP, Barrow BJ, Ashton WS et al. Aberrant crypts: putative pre-neoplastic foci in human colonic mucosa. Cancer Res. 1991; 51: 1564.
16. Cheng H, Bjerknes M, Amar J et al. Crypt production in normal and diseased human colonic epithelium. Anat. Rec. 1986; 319: 44.
17. Hurlstone DP, Fujii T, Lobo AJ. Early detection of colorectal cancer using high-magnification chromoscopic colonoscopy. Br. J. Surg. 2002; 89: 272-82.
18. Fujii T, Saito Y. The correspondence of magnifying endoscopic diagnosis and pathological diagnosis. Stomach Intestine 1999; 34: 1653-64.
19. Kudo S, Rubio CA, Teixeira CR et al. Pit pattern in colorectal neoplasia: endoscopic magnifying view. Endoscopy 2001; 33: 367-73.
20. Kudo S, Kashida H, Nakajima T et al. Endoscopic diagnosis and treatment of early colorectal cancer. World J. Surg. 1997; 21: 694-701.
21. Jaramillo E, Watanabe M, Slezak P et al. Flat neoplastic lesions of the colon and rectum detected by high-resolution video endoscopy and chromoscopy. Gastrointest. Endosc. 1995; 42: 114-22.
22. Kato S, Fujii T, Koba I et al. Assessment of colorectal lesions using magnifying colonoscopy and mucosal dye spraying: can significant lesions be distinguished? Endoscopy 2001; 33: 306-10.
23. Tung SY, Wu CS, Su MY. Magnifying colonoscopy in differentiating neoplastic from non-neoplastic colorectal lesions. Am. J. Gastroenterol. 2001; 96: 2628-32.
24. Otori K, Sugiyama K, Haseve T et al. Emergence of adenomatous aberrant crypt foci (ACF) from hyperplastic ACF with concomitant increase in cell proliferation. Cancer Res. 1995; 55: 4743-6.
25. Fenoglio-Preiser CM, Noffsinger A. Aberrant crypt foci. Toxicol. Pathol. 1999; 27: 632-42.
26. Fairman MP. DNA polymerase delta/PCNA: actions and interactions. J. Cell Sci. 1990; 95: 1-4.
27. McCormick D, Hall PA. The complexities of proliferating cell nuclear antigen. Histopathology 1992; 21: 591-4.
28. Gerdes J, Lemke H, Baisch H et al. Cell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal antibody Ki-67. J. Immunol. 1984; 133: 1710-15.
29. Sawhney N, Hall PA. Ki-67: structure, function and new antibodies. J. Pathol. 1992; 168: 161-2.
30. Riddell RH, Goldman H, Ransohoff DF et al. Dysplasia in inflammatory bowel disease. Standardized classification with provisional clinical applications. Hum. Pathol. 1983; 14: 931.
31. Di Gregorio C, Losi L, Fante R et al. Histology of aberrant crypt foci in the human colon. Histopathology 1997; 30: 328.
32. Otori K, Konishi M, Sugiyama K et al. Infrequent somatic mutation of the adenomatous polyposis coli gene in aberrant crypt foci of the human colon tissue. Cancer 1998; 83: 896.
33. Yamashita N, Minamoto T, Ochiai A et al. Frequent and characteristic K-ras activation and absence of p53 protein accumulation in aberrant crypt foci of the colon. Gastroenterology 1995; 108: 434.
34. Siu IM, Pretlow TG, Amini SB et al. Identification of dysplasia in human colonic aberrant crypt foci. Am. J. Pathol. 1997; 150: 1805.
35. Roncucci L, Modica S, Pedroni M et al. Aberrant crypt foci in patients with colorectal cancer. Br. J. Cancer 1998; 77: 2343.
36. Jen J, Powell SM, Papadopoulos N et al. Molecular determinants of dysplasia in colorectal lesions. Cancer Res. 1994; 54: 5523.
37. Shpitz B, Bomstein Y, Mekori Y et al. Aberrant crypt foci in human colons. Distribution and histomorphic characteristics. Hum. Pathol. 1998; 29: 469.
38. Bouzourene H, Chaubert P, Seelentag W et al. Aberrant crypt foci in patients with neoplastic and non-neoplastic colonic disease. Hum. Pathol. 1999; 30: 66.
39. Konstantakos AK, Siu IM, Pretlow TG et al. Human aberrant crypt foci with carcinoma in situ from a patient with sporadic colon cancer. Gastroenterology 1996; 111: 772.
40. Bird RP, McLellan EA, Bruce WR. Aberrant crypts, putative precancerous lesions, in the study of the role of diet in the aetiology of colon cancer. Cancer Surv. 1989; 8: 189-200.
41. McLellen EA, Medline A, Bird RP. Dose-response and proliferative characteristics of aberrant crypt foci: putative pre-neoplastic lesions in the rat colon. Carcinogenesis 1991; 12: 2093-8.
42. Roncucci L, Pedroni M, Fante R et al. Cell kinetic evaluation of human colonic aberrant crypts. Cancer Res. 1993; 53: 3726-9.
43. Lipkin M. Biomarkers of increased susceptibility to gastrointestinal cancer: new application to studies of cancer prevention in human subjects. Cancer Res. 1988; 48: 235-45.
44. Pretlow TP, O'Riordan MA, Somich GA et al. Aberrant crypts correlate with tumour incidence in F344 rats treated with azoxymethane and phytate. Carcinogenesis 1992; 13: 1509-12.
45. Pretlow TP, O'Riordan MN, Pretlow TG et al. Aberrant crypts in human colonic mucosa: putative preneoplastic lesions. J. Cell. Biochem. 1992; 16: 55-62.
46. Sandforth F, Heimpel S, Balzer T et al. Characterisation of stereomicroscopically identified neoplastic lesions during dimethylhydralazine- induced colonic carcinogenesis. Eur. J. Clin. Invest. 1988; 18: 655-62.
47. Yokota T, Sugano K, Kondo H et al. Detection of aberrant crypt foci by magnifying colonoscopy. Gastrointest. Endosc. 1997; 46: 61-5.
48. Bertoni G, Sassatelli R, Nigrisoli E et al. First observation of microadenomas in the ileal mucosa of patients with familial adenomatous polyposis and colectomies. Gastroenterology 1995; 109: 374-80.
49. Dolara P, Caderni G, Lancioni L et al. Aberrant crypt foci in human colon carcinogenesis. Cancer Detect. Prev. 1997; 21: 134-40.
50. Kerr JFR, Wyllie AH, Currie AR. Apoptosis: a basic biological phenomena with wide-ranging implications in tissue kinetics. Br. J. Cancer 1972; 26: 239.
51. Payne CM, Bernstein H, Bernstein C, Garewal H. Role of apoptosis in biology and pathology: resistance to apoptosis in colon carcinogenesis. Ultrastruct. Pathol 1995; 19: 221-48.
52. Potten CS, Kellett M, Roberts SA, Rew DA, Wilson GD. Measurement of in vitro proliferation in human colorectal mucosa using bromodeoxyuridine. Gut 1992; 33: 71-8.
53. Strater J, Koretz K, Gunthert AR, Moller P. In situ detection of enterocyte apoptosis in normal colonic mucosa and in familial adenomatous polyposis. Gut 1995; 37: 819-25.
54. Piazza GA, Rahm AL, Krutzsch M et al. Antineoplastic drugs sulindac sulphide and sulfone inhibit cell growth by inducing apoptosis. Cancer Res, 1995; 55: 3110-16.
55. Premoselli F, Sesca E, Binasco V, Caderni G, Tessitore L. Fasting/re-feeding before initiation enhances the growth of aberrant crypt foci induced by azoxymethane in rat colon and rectum. Int. J. Cancer 1998; 77: 286-94.
56. Arai T, Kino I. Role of apoptosis in modulation of the growth of human colorectal tubular and villous adenomas. J. Pathol. 1995; 176: 37-44.
57. Garewal H, Bernstein H, Bernstein C, Sampliner R, Payne C. Reduced bile acid-induced apoptosis in 'normal' colorectal mucosa: a potential biological marker for cancer risk. Cancer Res. 1996; 56: 1480-3.
58. Losi L, Roncucci L, Di Gregorio C et al. K-ras and p53 mutations in human colorectal aberrant crypt foci. J. Pathol. 1996; 178: 259-63.
59. Soh K, Yannnagisawa A, Hiratsuka H et al. Variation in K-ras codon 12 point mutation rate with histological atypia within individual colorectal tumours. Jpn. J. Cancer Res. 1993; 84: 388-93.
60. Vogelstein B, Fearon ER, Hamilton SR et al. Genetic alteration during colorectal-tumor development. N. Engl. J. Med. 1988; 319: 525-32.
61. Smith AJ, Stern HS, Penner M et al. Somatic APC and K-ras codon 12 mutations in aberrant crypt foci from human colons. Cancer Res. 1994; 54: 5527-30.
62. Miyaki M, Konishi M, Kikuchi-Yanoshita R et al. Characteristics of somatic mutation of the adenomatous polyposis coli gene in colorectal tumours. Cancer Res. 1994; 54: 3011-20.
63. Nakamura Y. The adenomatous polyposis coli gene and human cancers. J. Cancer Res. Clin. Oncol. 1995; 121: 529-34.
64. Kobayashi M, Watanabe H, Ajioka Y et al. Effect of K-ras mutation on morphogenesis of colorectal adenomas and early cancers: relationship to distribution of proliferating cells. Hum. Pathol. 1996; 27: 1042-9.
65. Shivapurkar N, Tang Z, Ferreira A, Nasim S, Garett C, Alabaster O. Sequential analysis of K-ras mutations in aberrant crypt foci and colonic tumours induced by azoxymethane in Fischer-344 rats on high-risk diet. Carcinogenesis 1994; 15: 775-8.
66. Polyak K, Hamilton SR, Vogelstein B. Early alteration of cell-cycle-regulated gene expression in colorectal neoplasia. Am. J. Pathol. 1996; 149: 381-7.
67. Augenlicht LH, Richards C, Corner G, Pretlow TP. Evidence for genomic instability in human colonic aberrant crypt foci. Oncogene 1996; 12: 1767-72.
68. Keinen CD, Shivapurkar N, Tang Z, Groden J, Alabaster O. Microsatellite instability in aberrant crypt foci from human colons. Cancer Res. 1996; 56: 5339-41.
69. Otori K, Sugiyama K, Haseve T et al. Emergence of adenomatous aberrant crypt foci (ACF) from hyperplastic ACF with concomitant increase in cell proliferation. Cancer Res. 1995; 55: 4743-6.
70. Wolber RA, Owen DA. Flat adenomas of the colon. Hum. Pathol. 1991; 22: 70-4.
71. Winawer SJ, Zauber AG, Ho MN et al. Prevention of colorectal cancer by colonoscopic polypectomy. The National Polyp Study Workgroup. N. Engl. J. Med. 1993; 329: 1977-81.
72. Roncucci L, Stamp D, Medline A et al. Identification and quantification of aberrant crypt foci and microadenomas in the human colon. Hum. Pathol. 1991; 22: 287-94.
73. Office of Population Censuses and Surveys. Cancer Statistics. Registration of Cases of Diagnosed Cancer Registered in England and Wales. Series MBI, no. 19. London: HMSO, 1983.
74. American Cancer Society. Cancer Facts and Figures. Atlanta, GA: American Cancer Society, 1995.
75. McMichael AJ, Giles GG. Cancer in migrants to Australia: extending the descriptive epidemiological data. Cancer Res. 1988; 48: 751-6.
76. Steele VE, Moon RC, Lubet RA et al. Preclinical efficacy evaluation of potential chemopreventive agents in animal carcinogenesis models: methods and results from the NCI chemoprevention drug development programme. J. Cell. Biochem. Suppl. 1994; 20: 32-54.
77. Wargovich MJ, Harns C, Chen C et al. Growth kinetics and chemoprevention of aberrant crypts in the rat colon. J. Cell. Biochem. Suppl. 1992; 16C: 51-4.
78. Moen CJA, Van der Valk MA et al. Different genetic susceptibility to aberrant crypt and colon adenomas in mice. Cancer Res. 1996; 56: 2382-6.
79. Oshima H, Oshima M, Taketo MM. Morphologic and molecular processes of polyp formation in APC knockout mice. Cancer Res. 1997; 57: 1644-9.
80. Kinzler KW, Vogelstein B. Lessons from hereditary colorectal cancer. Cell 1996; 87: 159-70.